In addition, as chromosome 9p24.1 amplification has been correlated with the efficacy of PD-1 blockade in Hodgkin lymphoma [48], it would be interesting to investigate the biomarker value of IGHV SHMhigh and IGV ongoing SHM for clinical response to PD-1 blockade immunotherapy in DLBCL, which showed associations with 9p24.1 amplification and PD-1 expression in the current study. Here, PDCD1 is linked to diffuse large B-cell lymphoma.